Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Patients with advanced melanoma who receive lifileucel — a tumor-infiltrating lymphocyte (TIL) therapy — face a low risk of serious side effects after leaving the hospital, a new study shows. Only 3.9% developed new severe treatment-related adverse events, and just 7.8% were readmitted for therapy-related reasons. Researchers say this supports a less intensive post-discharge monitoring approach compared to CAR-T therapy protocols.
A new retrospective study out of Memorial Sloan Kettering Cancer Center offers reassuring news for patients with advanced melanoma receiving lifileucel (Amtagvi), a tumor-infiltrating lymphocyte (TIL) therapy. Researchers found that serious treatment-related adverse events (TRAEs) after hospital discharge are uncommon — and when they do occur, they tend to show up within the first few months.
The study tracked 51 patients discharged after lifileucel treatment between October 2020 and October 2024. Over a median follow-up of 5 months, 65% experienced at least one adverse event, but severe cases were rare. The findings suggest that the intensive post-discharge monitoring protocols typically used for CAR-T therapy may not be necessary for most lifileucel patients.
By the Numbers
Why it matters: As TIL therapy becomes a standard option for anti-PD1 refractory advanced melanoma, understanding post-discharge risks is critical for shaping real-world care. Less intensive follow-up could meaningfully improve patients' quality of life and expand access to care in this growing population.
